With the opioid epidemic charging ahead into 2024, new technology continues to crop with the goal of expanding access to tools that save lives.
A person dies every five minutes in America from a drug overdose, Rahul Gupta, who heads up the White House Office of National Drug Control Policy, said during an American Medical Association conference earlier in the year.
As with much of the U.S., in Allegheny County the leading driver of those deaths is synthetic opioid fentanyl, which is linked to 85% of drug overdose deaths in the county, according to preliminary data from the Health Department’s overdose dashboard.
Narcan, the brand name for the drug naloxone, has become more of a household name in recent years. Naloxone blocks opioids from binding in the brain and can reverse an overdose from fentanyl and other opioids. While emergency medical services have had Narcan as part of their tool kit for decades, there’s been a push among some groups to arm as many people as possible with the medication.
Approved for over-the-counter sale in March, Narcan hit shelves in September. While harm reduction experts support expanding access, they worry the $45 price tag — for two 4-milligram doses of the nasal spray — remains inaccessible for many, or that simply not enough people have it on their person when they need it.
Narcan is given out for free by Prevention Point Pittsburgh, Endoverdose.org and NextDistro.org, among other places.
Myriad advancements, some new, others in-the-works, aim to tackle cost, accessibility and stigma. Here are a few.
A new nasal spray option
Opvee, created by pharmaceutical company Indivior, was FDA-approved as a prescription medication in May to treat opioid overdose and is still becoming available nationwide.
The active ingredient, nalmefene, works similarly to naloxone by blocking opioid chemicals from docking in the brain. It also comes as a nasal spray, with a lower dose at 2.7 milligrams versus Narcan’s 4 milligrams. (RiVive, another naloxone nasal spray, contains 3 milligrams of naloxone.)
Supporters see the addition of Opvee as another option consumers and first responders can choose to help reduce overdose deaths.

“As we continue to see health challenges evolve, our tool kits have to evolve,” said Jerome Adams, former U.S. Surgeon General and an Opvee paid consultant. “I want people to understand we need every tool in the tool chest.”
While Opvee and Narcan are similar, they differ in some ways. Adams said Opvee was designed “with fentanyl in mind,” with a potency that better matches fentanyl and stays in the body longer than naloxone.
This also means it could have more side effects and contribute to feelings of withdrawal after revival.
As of late November, Opvee was available in 12 states with statewide standing orders. While Pennsylvania is not one of them, it is available in Ohio. It costs $37.50 for one dose and $75 for a two-dose pack.
“Indivior is committed to making OPVEE widely available to consumers to help save lives,” a company spokesperson said in an email.
Shattering stigma with discretion
Beginning as a commercial fishing project in an industrial design class in a sleepy Pacific Northwest town, Nove is on its way to becoming an available product.
A key-chain attachable device with naloxone inside, the aim is to increase the accessibility of carrying the medication while maintaining discretion.
It dates to the spring of 2022, when Brendan Mudd, now 23, of Carmel, Ind., was doing research for a class and noticed that the opioid overdose rate among commercial fishermen was high. Bellingham, Wash., where Mudd attended college, sits on the Puget Sound and has a robust fishing industry.

Mudd, Nove’s founder, visited a syringe service program in Bellingham, where he spoke to volunteers. They didn’t want to carry traditional Narcan out of fear of judgment. Others said Narcan’s packaging, in a plastic blister case, doesn’t easily fit into pockets.
“I didn’t know anyone who carried Narcan,” Mudd said. “I hardly knew what it was before starting this project.”
Mudd, now living in San Francisco, and his co-founder, Charlie Brizz, are looking for partnerships while they wait to pursue FDA approval, which could take up to five years. In the meantime, they’ve thought up a new device: an accessory carrying case, similar to Airpods, that people can use to store and carry their previously purchased Narcan.
The team plans to partner with state and local governments to provide both products in bulk and distribute for free.
Triggering naloxone with blue light
Scientists at Boston Children’s Hospital and Harvard Medical School found that using blue light to trigger injected naloxone could successfully reverse morphine sedation in mice, providing hints to new technologies for humans down the line.
The study, published last month in the journal Nano Letters, was a proof-of-concept for using light to trigger the release of the drug. The scientists were motivated by observing access issues with Narcan and the “horrific” scope of the opioid epidemic.
“There is an antidote, which, if it’s given in a timely manner, is lifesaving, and that’s naloxone,” said Daniel Kohane, senior associate in critical care medicine in the Department of Anesthesiology at Boston Children’s Hospital and senior author on the paper.
But whether or not people have easy access to naloxone depends very much on where they live, he said, and how strong stigma reigns in that region.
Kohane and his lab’s ultimate idea is that someone could visit a clinic where they receive an injection under the skin. That injection would include a “polymer-naloxone conjugate” — a naloxone molecule chemically attached to a safe, biodegradable and FDA-approved polymer. The product would sit under the skin and release nothing until the exposure to strong blue light, which chemically breaks the naloxone off the polymer, leading to the naloxone circulating throughout the body.
The blue light could be added into a kind of medical alert bracelet that someone could turn on to trigger the naloxone if that person was overdosing.
Joshua Schulman, an emergency room attending physician at UPMC and an assistant professor of emergency medicine who was not involved in the study, said the proof of concept has potential.
The study is in early stages — the team plans to conduct more research on larger animals and to learn more about the triggerable release of the product. Only then could they think about moving to clinical trials in humans.
“In general, the idea is a good one,” said Schulman. “To answer the question, ‘Should there be more ways of getting Narcan to people who need it?’ The answer is always yes.”
Hanna Webster: hwebster@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.